Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mi-Dose Pharma is an India-based specialty pharmaceutical company that specializes in advanced drug delivery systems, with a primary focus on ophthalmology. The company utilizes its proprietary Mi-Dose technology to provide preservative-free, unit-dose medications that enhance patient safety and treatment efficacy. Their portfolio includes treatments for dry eye, glaucoma, and ocular allergies, leveraging Blow-Fill-Seal (BFS) manufacturing processes to ensure sterility and precision. By addressing the limitations of traditional multi-dose eye drop containers, Mi-Dose Pharma aims to reduce the risk of contamination and ocular surface toxicity. The company is positioned as an innovation-driven player in the global ophthalmic market, offering both proprietary products and partnership opportunities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mi-Dose Pharma.